Innate Pharma (IPHA) Current Assets (2017 - 2025)

Innate Pharma has reported Current Assets for 9 years, with the latest figure at $54.4 million in Q4 2025.

• For the quarter ending Q4 2025, Current Assets fell 40.66% year-over-year to $54.4 million; the trailing twelve-month figure through Dec 2025 stood at $54.4 million (down 40.66% YoY), and the FY2025 full-year result was $54.4 million, down 40.66% from the prior year.
• Current Assets for Q4 2025 stood at $54.4 million, down from $73.6 million in the prior quarter.
• The five-year high for Current Assets was $183.3 million in Q2 2022, with the low at $54.4 million in Q4 2025.
• Historically, Current Assets has averaged $129.7 million across 5 years, with a median of $149.4 million in 2021.
• Annual changes were most pronounced in 2021 — Current Assets plunged 99.9% — and 2022, when it gained 17.38%.
• Innate Pharma's Current Assets stood at $158.2 million in 2021, then decreased by 9.8% to $142.7 million in 2022, then gained by 11.63% to $159.3 million in 2023, then slumped by 42.47% to $91.6 million in 2024, then tumbled by 40.66% to $54.4 million in 2025.
• The last three Current Assets figures came in at $54.4 million (Q4 2025), $73.6 million (Q2 2025), and $91.6 million (Q4 2024), per Business Quant data.